ReviewCNS drugs2009
Utility of atypical antipsychotics in the treatment of resistant unipolar depression.
Review in CNS drugs, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.
- Second-generation antipsychotics for major depressive disorder and dysthymia.The Cochrane database of systematic reviews · 2010Pooled it
- Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial.BMC psychiatry · 2011Trial
- Molecular mechanisms of olanzapine against agitation in schizophrenia and bipolar disorder based on network pharmacology and molecular docking.Scientific reports · 2025Article
- Incidence of Neuroleptic Malignant Syndrome During Antipsychotic Treatment in Children and Youth: A National Cohort Study.Journal of child and adolescent psychopharmacology · 2024Article
- Central serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?Frontiers in pharmacology · 2015Review
- Profile of aripiprazole in the treatment of bipolar disorder in children and adolescents.Adolescent health, medicine and therapeutics · 2014Review
- Efficacy and tolerability of pharmacotherapy options for the treatment of irritability in autistic children.Clinical medicine insights. Pediatrics · 2014Review
- 5-HT₂A receptor inactivation potentiates the acute antidepressant-like activity of escitalopram: involvement of the noradrenergic system.Experimental brain research · 2013Article
- Drug-drug conditioning between citalopram and haloperidol or olanzapine in a conditioned avoidance response model: implications for polypharmacy in schizophrenia.Behavioural pharmacology · 2012Article
- Efficacy and safety of aripiprazole in child and adolescent patients.European child & adolescent psychiatry · 2012Review
- Effects of sustained administration of quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and serotonin transmission.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2012Article
- The role of antipsychotics in the management of fibromyalgia.CNS drugs · 2012Review
- Antidepressant prescribing patterns in Korea: results from the clinical research center for depression study.Psychiatry investigation · 2011Article
- Elderly patients with schizophrenia and depression: diagnosis and treatment.Clinical schizophrenia & related psychoses · 2011Review
- Olanzapine/fluoxetine: a review of its use in patients with treatment-resistant major depressive disorder.CNS drugs · 2010Review
- Pharmacological and combined interventions for the acute depressive episode: focus on efficacy and tolerability.Therapeutics and clinical risk management · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Many patients fail to achieve an adequate response to antidepressant medication. Growing evidence suggests that atypical antipsychotics may augment antidepressant effects, resulting in a greater potential for response. Atypical antipsychotics possess pharmacological actions that are associated with antidepressant properties, including serotonin 5-HT(2) receptor antagonist and 5-HT(1A) and dopamine receptor partial agonist activity. In fact, the term 'atypical antipsychotic' is an unfortunate remnant of the early indication of these drugs in the treatment of schizophrenia. Soon after their introduction, the usefulness of atypical antipsychotics in bipolar disorder was firmly established and their use in the treatment of mood disorders has far outpaced their use in schizophrenia and other psychotic disorders. Aripiprazole has become the first agent to receive US FDA approval for the adjunctive treatment of unipolar depression. Most recently, Symbyax, a fluoxetine/olanzapine combination, received FDA approval for the acute treatment of treatment-resistant depression. This is the first medication to be FDA approved for this indication. In the present article, the usefulness of antipsychotics in the treatment of resistant unipolar depression is reviewed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.